Ir directamente a la navegación principal
Ir directamente a la búsqueda
Ir directamente al contenido principal
Clasificar por
Keyphrases
Type 2 Diabetic Patients
100%
Hypovitaminosis D
88%
Metabolic Syndrome
86%
Glycemic Control
80%
Bariatric Surgery
64%
Type 2 Diabetes Mellitus (T2DM)
61%
Spain
46%
Sex at Birth
43%
Diabetic Patients
43%
Familial Combined Hyperlipidemia
43%
High-density Lipoprotein Cholesterol (HDL-C)
38%
Low-density Lipoprotein
33%
Obesity
30%
Vitamin D Status
29%
Diabetes
29%
Inflammation
28%
Hypoglycemia
28%
First Trimester
27%
Hemoglobin A1c (HbA1c)
27%
Confidence Interval
26%
Electronegative LDL
25%
Inflammatory Effects
25%
Triglyceride Level
25%
Apolipoprotein J
24%
Odds Ratio
23%
25(OH)D Concentration
22%
Antrum
21%
Dense LDL
21%
Individualized Glycemic Targets
21%
Glycemic Targets
21%
Stages of Change
21%
Inositol
21%
Glucose Homeostasis
21%
Meta-analysis of Randomized Controlled Trials
21%
Weight Management
21%
Laparoscopic Sleeve Gastrectomy
21%
Systematic Meta-analysis
21%
Randomized Trial
21%
GLP-1 Receptor Agonist
21%
Prandial
21%
Weight Loss Outcomes
21%
Gastric Emptying
21%
Lipid-lowering Treatment
21%
Apolipoprotein A-I (ApoA-I)
21%
Change Process
21%
Cirrhosis
21%
Type 1 Diabetes Mellitus (T1DM)
21%
Truncated Forms
21%
Primary Care Patients
21%
Type I Diabetes
21%
Pharmacology, Toxicology and Pharmaceutical Science
Hypovitaminosis D
90%
Maturity Onset Diabetes of the Young
88%
Metabolic Syndrome X
86%
Inflammation
67%
Diabetes Mellitus
58%
Vitamin D
48%
Familial Hyperlipemia
43%
Low Density Lipoprotein
40%
Hemoglobin A1c
39%
High Density Lipoprotein
36%
Hypoglycemia
32%
Triacylglycerol
28%
Fatty Acid
24%
Clusterin
24%
Lipoprotein
23%
Omeprazole
21%
Inositol
21%
Insulin Dependent Diabetes Mellitus
21%
Randomized Controlled Trial
21%
Glucagon Like Peptide 1 Receptor Agonist
21%
Hypercholesterolemia
21%
Cell Receptor
21%
Cytotoxicity
21%
Congestive Heart Failure
21%
Biological Marker
21%
Diseases
16%
Antidiabetic Agent
15%
Carcinogenicity
14%
Growth Differentiation Factor 15
14%
Enzyme-Linked Immunosorbent Assay
13%
Dyslipidemia
13%
Normal Human
12%
1 Alkyl 2 Acetylglycerophosphocholine Esterase
12%
C Reactive Protein
11%
Prevalence
10%
Galectin 3
10%
Insulin Resistance
10%
25 Hydroxyvitamin D
10%
Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor
9%
Cytokine
9%
Coronary Artery Disease
8%
Ceramide
8%
Cross-Sectional Study
8%
Morbid Obesity
7%
Scavenger Receptor
7%
Fibronectin
7%
Glycosaminoglycan
7%
Serum Amyloid A
7%
Low Density Lipoprotein Receptor
7%
Glycosylated Hemoglobin
7%
Biochemistry, Genetics and Molecular Biology
Glycemic Control
80%
Hypovitaminosis D
68%
Low-Density Lipoprotein
61%
Lipoprotein
52%
Vitamin D
50%
Lipid
43%
Combined Hyperlipidemia
43%
High-Density Lipoprotein
36%
Blood Level
26%
Metabolic Regulation
25%
Clusterin
24%
Triglyceride
23%
Triacylglycerol Level
21%
LRP1
21%
Hypercholesterolemia
21%
Individualization
21%
Apolipoprotein
21%
Cathepsin D
21%
Cytotoxicity
21%
Sex Ratio
21%
Atrial Natriuretic Peptide
21%
Cardiac Muscle Cell
21%
Secretome
21%
Growth Differentiation Factor
21%
Cross Sectional Study
20%
Insulin Resistance
16%
Galectin-3
16%
Prevalence
14%
Lipoprotein-Associated Phospholipase A2
12%
Statin
12%
C-Reactive Protein
11%
Surface Area
10%
Lipid Profile
8%
Blood Plasma
7%
Immunoassay
7%
Ceramide
7%
Chi-Square Testing
7%
Explant
7%
Mann-Whitney U Test
7%
Coronary Artery Disease
7%
Student's t-Test
7%
Very Low-Density Lipoprotein
7%
Binding Affinity
7%
Serum (Blood)
7%
Animal Models
7%
Amino Acids
7%
Proteomics
7%
Lipid Metabolism
7%
Antioxidant Activity
7%
Enzyme
7%
